Abstract:While it is now accepted that the gut microbiota contribute to the genotype-environment-lifestyle interactions triggering inflammatory bowel disease (IBD) episodes, efforts to identify the pathogen(s) that cause these diseases have met with limited success. The advent of culture-independent techniques for characterizing the structure and/or function of microbial communities (hereafter referred to as metagenomics) has provided new insights into the events associated with the onset, remission and recurrence of IBD. A large number of observational and/or case-control studies of IBD patients have confirmed substantive changes in gut bacterial profiles (dysbiosis) associated with disease. These types of studies have been augmented by new profiling approaches that support the identification of more ‘colitogenic' bacteria from numerically predominant taxa. Evidence of alterations in lesser abundant taxa such as the methanogenic archaea, to favor types that are more immunogenic, has also been forthcoming. Several recent longitudinal studies of patients with Crohn's disease have produced additional insights, including evidence for the role of ‘anti-inflammatory' microbiota in providing a protective effect and/or promoting remission. In summation, the implications of dysbiosis and restoration of a ‘healthy microbiota' in IBD patients requires definition beyond a taxonomic assessment of the changes in the gut microbiota during disease course. The available evidence does suggest that specific members of the gut microbiota can contribute either pro- or anti-inflammatory effects, and their ecological fitness in the large bowel affects the onset and recurrence of IBD. While metagenomics and related approaches offer the potential to provide novel and important insights into these microbiota and thereby the pathophysiology of IBD, we also need to better understand factors affecting the ecological fitness of these microbes, if new treatment of IBD patients are to be delivered.

Animal models of inflammatory bowel disease: novel experiments for revealing pathogenesis of colitis, fibrosis, and colitis-associated colon cancer

[Research Progress on Composite Animal Models of Inflammatory Bowel Disease Based on Gene Knockout].

Animal models of inflammatory bowel disease: category and evaluation indexes

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Research progress in genetic animal models of inflammatory bowel disease

Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis

Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model

Microbiota of Inflammatory Bowel Disease Models.

Integrated multi-model analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD

Application of Zebrafish Models in Inflammatory Bowel Disease.

Association between intestinal microbiota and inflammatory bowel disease

General view in animal model of inflammatory bowel disease

Mouse Models of Colitis-Associated Colon Cancer

Characterization and Analysis of the Temporal and Spatial Dynamic of Several Enteritis Modeling Methodologies

An in vitro model to study immune activation, epithelial disruption and stromal remodelling in inflammatory bowel disease and fistulising Crohn's disease

Diagnostic imaging advances in murine models of colitis

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

T cell transfer model of colitis: a great tool to assess the contribution of T cells in chronic intestinal inflammation

An Important Model for Exploring the Pathways of Inflammatory Bowel Disease (IBD) in the Intestinal Tract

Immunopathogenesis of Colitis-Associated Cancer in an Animal Model.

Leveraging Organ‐on‐Chip Models to Investigate Host–Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease